🟢 MannKind surges 6% today on FDA approval of Furoscix ReadyFlow™ and $50M private placement

MannKind is trading about 6% up today at $4.11 following two significant announcements:

• The U.S. Food and Drug Administration (FDA) approved Furoscix ReadyFlow™, a new autoinjector for treating edema in adults with heart failure or chronic kidney disease. This approval came ahead of schedule and was an unexpected positive surprise.
• The company also announced a $50 million private placement to institutional investors, significantly strengthening its cash position.
• These company-specific events are the primary drivers of today's price action.